About this Research Topic
Protein ubiquitination is a powerful post-translational modulator of cellular functions and is tightly controlled by the action of hundreds of regulatory (E1, E2, E3) and deubiquitinating enzymes (DUBs). Unlike most post-translational modifiers such as phosphorylation or acetylation, ubiquitination can be highly customized through further post-translational modification of ubiquitin itself, thereby coding for a distinct cellular outcome. Dysregulation of this intrinsic process is often associated with diseases that include cancer, autoimmunity, Alzheimer, and Parkinson’s disease.
Next to ubiquitin, a number of ubiquitin-like proteins (e.g. Sumo, Nedd8, Isg15, Ufm1, Fat10) can also be attached to proteins increasing the complexity of and fine-tuning cellular responses even further. To advance our understanding of one of the most complex and widespread signaling networks in biology, activity-based probes (ABPs), assay reagents as well as advanced proteomics techniques are key. Characterization of this dynamic field is imminent as the development of inhibitors of Ubiquitin(-like) system components has gained significant increase in interest recently.
The aim of the current Research Topic is to cover promising, recent, and novel research trends in the ubiquitin and ubiquitin-like field. Areas to be covered in this Research Topic may include, but are not limited to:
- Development of Activity Based Probes
- Application of the ubiquitin(-like) based toolbox in the study of the ubiquitin landscape
- Therapeutic strategies (e.g Assay development, PROTACs)
- Ubiquitin(-like) variants
- Advanced proteomic techniques
Keywords: Ubiquitin(-like), Activity-based probes, toolbox, applications, inhibitors
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.